Immunyx is a drug development company focused on modulating neutrophil function to treat disease. Numerous high burden illnesses such as COPD, cancer, and arthritis involve deregulated neutrophils which exacerbate and sometimes cause the underlying pathology. Using our platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Currently there are no FDA approved drugs targeting neutrophil activity in disease, providing Immunyx the potential to provide first in class therapies for a variety of diseases.
CEO: Seth Salpeter
